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INTRODUCTION: SARS-CoV-2 is a novel virus from the coronavirus family that emerged in 
the Hubei province of China in December 2019 and rapidly spread throughout the world. On 
March 11, 2020, the World Health Organization declared a global pandemic. Infection with 
SARS-CoV-2 causes coronavirus disease 19 (COVID19) which can be fatal. There is an obvious 
and pressing need for research surrounding SARS-CoV-2 that will aid in eradication of this 
pandemic.  
OBJECTIVE: The goal of this study was to absolve the dire need for small animal models of 
human disease that demonstrate hallmark pathological features of infection. Due to ethical and 
financial obstacles, the use of animals that closely resemble human immunity, such as non-human 
primates, is often not a viable option. For this reason, there is a push to develop small animal 
models that can mimic human disease responses, particularly those in viral infections that have a 
narrow species tropism. To achieve this in the context of the novel coronavirus, SARS-CoV-2, 
we studied various mouse models and their capacity to become infected with and mount an 
immune response to SARS-CoV-2. Our goal was to identify a model that sufficiently mimics 
severe COVID19 seen in humans as well as provide molecular insight into pathways that prevent 
the development of severe disease. 
METHODS: NRG-L and HIS-NRGF-L mice were subcutaneously implanted with human fetal 
lung xenografts and infected with SARS-CoV-2. Tissues were stained with H&E for 
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histopathological scoring. NRG-L and HIS-NRGF-L tissues were fluorescently labeled using 2 
different multiplex immunohistochemistry panels. Slides were digitized by a Vectra Polaris™ 
fluorescent whole slide scanner and digital analysis was completed using HALO™. Statistical 
analysis was conducted using GraphPad Prism™ 9.0.1.  
RESULTS: Infected NRG-L mice present extensive histopathological manifestations when 
compared to uninfected controls. Cumulative histology scores at both 2 and 7DPI were increased 
when compared to uninoculated fLX. Neutrophil influx, intra-airspace necrosis, capillary fibrin 
thrombi, and presence of syncytial cells were the most significant independent observations that 
contributed to the increased cumulative score. Together these findings indicate that fLX 
inoculated with SARS-CoV-2 faithfully recapitulate several features of diffuse alveolar damage 
(DAD) described in severe COVID-19. HIS-NRGF-L mice displayed decreased influx of 
neutrophils, intra-airway necrosis, and syncytial cells when compared to NRG-L fLX. 
Hemorrhage was decreased at both 2 and 7 DPI for HIS-NRGF-L fLX compared to NRG-L fLX. 
Cumulative histology scores were decreased in HIS-NRGF-L fLX at 7 DPI when compared to 
NRG-L fLX. Taken together these findings support the hypothesis that human myeloid and 
lymphoid infiltrates suppress or prevent the disparate host response observed in NRGL-L fLX 
that manifested in pronounced diffuse alveolar damage. 
CONCLUSION: Using digital image analysis of multiplex immunohistochemistry paired with 
semi-quantitative histopathological scoring, this study characterized important hallmark lesions 
observed in severe COVID19 as seen in small animal models. NRG-L and HIS-NRGF-L mice 
that are subcutaneously implanted with human fetal lung xenografts are susceptible to infection 
with SARS-CoV-2 and can produce severe and moderate disease phenotypes respectively. Co-
engraftment with human fetal lung tissue and human immune system components in HIS-NRGF-
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L mice suppresses the divergent host response that is observed in NRG-L mice. For this reason, 
NRG-L mice engrafted with fLX are an ideal small animal model of severe COVID19, whereas 
HIS-NRGF-L mice severe as a valuable and informative model for deciphering molecular 
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SARS-CoV-2 Background  
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh 
coronavirus known to infect humans. The most notable of these viruses that can result in 
severe clinical disease prior to December 2019 are severe acute respiratory syndrome-
coronavirus (SARS-CoV) and Middle East Respiratory Syndrome-coronavirus (MERS-
CoV). The 2002 outbreak of SARS-CoV originated in the Guangdong province of China 
and rapidly spread to other countries via international travel [1]. The virus ultimately 
reached five continents and killed 774 people. MERS-CoV emerged in the Arabian 
Peninsula in 2012 and continues to remain a public health concern with 223 confirmed 
new cases in the 2019 calendar year [2]. In December of 2019, a previously unknown 
CoV emerged in the Hubei province of China [3]. This virus, now known as SARS-CoV-
2, has spread to 6 continents and infected over 116 million people. To date, over 2.5 
million people have died as a result of SARS-CoV-2 infection [4]. Each of the 3 
aforementioned viruses can cause severe disease, manifesting as acute pneumonia and 
potential death. The zoonotic origin of SARS-CoV-2 is still unknown, although it is 
believed to have originated in bats. Previous research surrounding SARS-CoV 
determined that palm civets and racoon dogs were intermediate hosts for zoonotic 
transmission of SARS-CoV from bats to humans in the 2002 SARS epidemic. In the case 
of MERS, the intermediate host has been recognized as dromedary camels [5]. However, 
the intermediate host between bats and humans for SARS-CoV-2 is still unknown. 
Although not confirmed, the virus has been traced back to a seafood market in Wuhan, 
 
2 
where sale of nonaquatic animals such as birds, bats, and rabbits is considered a potential 
bridge between zoonotic and human infection. It is unclear as to why coronavirus 
outbreaks are reoccurring predominantly in China, but one can speculate that these 
viruses are circulating mostly in animals found in China as opposed to other parts of the 
world. Additionally, Chinese culture and traditional medicine involving close interactions 
with wild animals in wildlife markets as well as consuming raw animal tissues could 
potentially play a role in the bridge of zoonotic to human disease [6].  
As humanity becomes increasingly interconnected due to accessibility of global travel, 
diseases have more opportunity to disperse than ever before. Subsequently, this also 
makes containment of a highly contagious pathogen even more challenging. This has 
been made abundantly clear with the current coronavirus pandemic, as early efforts to 
contain the virus were unsuccessful. Despite originating in Asia, dissemination of SARS-
CoV-2 has predominated in the Americas and Europe, with the most reported cases 
occurring in the United States, India, and Brazil [4]. Recent analyses indicate that SARS-
CoV-2 is more infectious and less virulent than SARS-CoV. Unfortunately, transmission 
is difficult to track in a virus such as this one because affected individuals often do not 
present with symptoms until many days after infection, or at all, thus creating a higher 
pandemic potential. The high percentage of asymptomatic and delayed-onset 
symptomatic cases produces a great challenge for halting transmission. 
Betacoronaviruses such as SARS-CoV-2 are known to spread from one individual to 
another though respiratory droplets, aerosol, surface contamination, and potentially 
through fecal-oral contamination. As of March 2021, there have been 3 different vaccines 
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granted emergency use authorization by the United States Food and Drug Administration 
[7]. Though this is a promising step in the effort to eradicate the COVID19 pandemic, 
vaccine supply is currently very limited and dose distribution is under strict guidelines, 
concentrating first on the elderly and other vulnerable populations [7]. Therefore, until 
vaccines are made widely available to the masses, we are limited in what preventative 
measures can be taken. Currently, the most effective methods of slowing the spread are 
case isolation, physical distancing, quarantine, and hygiene measures [8].   
SARS-CoV-2 structure and function 
Coronaviruses were discovered in the 1960s and designated to the Coronaviridae family. 
SARS-CoV-2 belongs to the subfamily Orthocoronavirinae and genus betacoronavirus. 
Betacoronaviruses circulate primarily in mammals and cause a variety of zoonotic 
diseases. Although infrequent, animal CoVs can infect humans, such as with SARS, 
MERS, SARS-2, and the common cold. Coronaviruses are spherical positive single-
stranded RNA viruses that contain spike proteins (S) which extend outward from the 
virion surface. The S protein is a highly glycosylated protein that facilitates viral entry 
into host cells. The receptor binding domain (RBD) within the S1 domain allows binding 
to host receptor while the S2 domain mediates the fusion between viral and host cell 
membrane that is necessary for entry. The primary receptor utilized in SARS-CoV-2 
infection is angiotensin-converting enzyme 2 (ACE2) [6]. Additionally, serine protease 
TMPRSS2 is required to access the S protein and facilitate host entry [9]. Tissue tropism 
of a specific coronavirus is determined by the S protein interaction with receptors on host 
cells. SARS-CoV-2 has a narrow tropism, meaning that the virus can only infect tissues 
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containing a receptor that has a high affinity interaction with the viral S protein [6]. 
Entrance into susceptible cells is a complex process that requires both receptor-binding 
and proteolytic processing of the S protein. It is hypothesized that S cleavage activates 
the protein by inducing extensive conformational changes that permit membrane fusion 
[3]. Tissue distribution of ACE2 in humans largely coincides with organ systems affected 
by COVID-19. Studies on SARS-CoV showed that expression of ACE2 predominates in 
the epithelia of the lung and small intestine with lower expression in venous endothelial 
cells and arterial smooth muscle [10]. These findings align with what is known about 
SARS-CoV-2 pathogenesis, as infection manifests principally in the lungs and can also 
include gastrointestinal involvement.  
Recent studies have demonstrated that SARS-CoV-2 may have additional cell entry 
mechanisms that are independent of ACE2 expression. One such study investigated 
SARS-CoV-2 infection in pulmonary epithelial cells and found that lung microbiota may 
play a role in viral dissemination. The results suggest that some bacteria and serotypes in 
the lung harbor rhamnosylated epitopes that could facilitate viral binding to lung 
epithelial cells, thus permitting infection in ACE2-negative cells [11]. Several mouse 
models have also suggested that there are likely alternative routes of infection in SARS-
CoV-2. A prior study completed in our lab focused on viral neuroinvasion in k18-hACE2 
mice (immunocompromised mice expressing human ACE2 under the k18 promoter). 
Results showed that viral dissemination in the brain did not align with spatio-temporal 
distribution of hACE2, indicating a discrepancy between cells containing viral antigen 
and cells expressing hACE2. The mechanism of neuroinvasion in SARS-CoV-2 infection 
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remains poorly understood, but these data suggest that there may be other routes of 
infection that do not utilize ACE2. Additional findings within the lungs of these mice 
showed that not all cells expressing hACE2 are permissive to infection. Furthermore, 
infection can be found in cells with sparse to absent expression of hACE2 such as AT1 
(alveolar type 1) cells, further solidifying the theory that this virus may have 
supplementary infection mechanisms not involving ACE2 [12].  
Unlike other group 2 betacoronaviruses, SARS-CoV-2 has a furin cleavage site (PRRAR) 
within its spike protein. Because it is absent in other viruses of this kind, the furin 
cleavage site has largely come into question as it pertains to infection and pathogenesis. It 
has been hypothesized that this unique cleavage site may be responsible for the high 
infectivity and transmissibility of SARS-CoV-2 [13]. Studies have shown that deletion of 
the furin cleavage site results in attenuated replication in human respiratory cell lines. 
Additionally, in-vivo studies using hamsters and K18-hACE2 transgenic mice showed 
that PRRA deletion results in less severe disease when compared to wild-type SARS-
CoV-2 infection. The results of this study indicate that infection with the attenuated virus 
yields sufficient immunity to protect against viral re-challenge in hamsters. As a whole, 
this data regarding the novel furin cleavage site is largely relevant in understanding the 
mechanism of SARS-CoV-2 infection [14]. Little is currently known about the immune 
targets of SARS-CoV-2 and there is even less knowledge on which parts of the virus 
illicit human immune responses. However, this novel virus exhibits a high level of 
sequence homology to SARS-CoV, which is well-categorized in the Immune Epitope 
Database and Analysis Resource (IEDB) catalog [15]. SARS-CoV-2 shares 79% genetic 
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similarity with SARS-CoV, and a staggering 98% genetic similarity with the bat 
coronavirus RaTG13, meaning there are likely similarities in their pathogeneses as well 
[9]. Researchers have used databases such as IEDB to compile known epitope sites of 
other coronaviruses and retroactively map them to corresponding regions of SARS-CoV-
2 to predict probable epitopes. Knowledge of viral epitopes could aid in vaccine design as 
well as a host of other medically relevant areas such as predicting potential mutation 
events. Using this method, researchers have predicted several potential SARS-CoV-2 B 
and T cell epitopes [15].  Studies have shown that most infected individuals develop 
neutralizing antibodies against the SARS-CoV-2 Spike protein, though titers vary among 
individuals. There is a clear correlation between antibody titers and severity of disease. 
Because current vaccines target the viral spike protein, production of antibodies and the 
human immune response is of great importance. A study on convalescent patients 
demonstrated that all patients had Spike-specific functional CD4+ T-cell responses that 
correlated with virus-specific IgG and IgA titers. Interestingly, 60% of individuals 
unexposed to SARS-CoV-2 harbored S-specific CD4+ T-cells and a smaller proportion 
also had virus-specific CD8+ T-cells. This could potentially be due to a cross-reactive 
immune response between SARS-CoV-2 and seasonal coronaviruses such as the common 
cold. A subsequent study mapped 142 T-cell epitopes across the SARS-CoV-2 genome 
and found the presence of pre-existing memory CD4+ T-cells that are cross reactive with 
similar affinity to common cold viruses HCoV-OC43, HCoV-229E, HCoV-NL63, and 
HCoV-HKU1. Using overlapping peptide pools corresponding to the C and N terminus 
of the S glycoprotein, researchers measured the frequency of which CD4+ T-cells 
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targeted each terminus. T-cells isolated from infected individuals targeted both the C and 
N terminus equally, whereas T-cells from healthy controls predominately targeted the C 
terminus. Incidentally, the C terminus of the SARS-CoV-2 Spike protein has a high 
homology with the S protein of the common cold coronaviruses [16]. This information is 
of immediate relevance in order to fully understand the human immune response to 
SARS-CoV-2. Since severe COVID-19 is considered to be the result of a dysregulated 
immune response, understanding the mechanism of both the normal and dysfunctional 
immune response is essential.  
Pathogenesis in humans  
Clinical manifestation of infection with SARS-CoV-2 varies greatly among 
demographics. Fatality rates are higher among elderly populations and those with 
preexisting medical conditions. Comorbid risk factors that have been identified in SARS-
CoV-2 are increased age, diabetes, cardiac dysfunction, hypertension, and cancer. In 
severe cases, the most frequent comorbidities observed are hypertension, diabetes, 
coronary artery disease, and obesity, all of which are predisposing factors affiliated with 
pro-inflammatory and pro-coagulative states [17]. Interestingly, preliminary studies have 
indicated that immunosuppression does not appear to be a risk factor for increased 
disease severity or mortality. This is true for both drug-induced and disease-induced 
immunosuppression [18].  This coincides with previously collected data related to the 
prior SARS and MERS outbreaks, where no evidence was found to show increased risk 
of infection or morbidity in immunocompromised individuals [19].  Infection with 
SARS-CoV-2 triggers an immune response that recruits macrophages and monocytes to 
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the site of infection. Cytokine release and priming of adaptive T and B cells also occurs. 
In most cases, this response is enough to absolve the infection. However, instances of a 
dysfunctional immune response are not uncommon, and these cases can result in severe 
health concerns. COVID-19 exhibits a varying fatality rate between the sexes. The male 
fatality rate is 2.8%, whereas it is only 1.7% in females. This may be due to the fact that 
ACE2 is located on the X chromosome. It is possible that certain alleles exist which 
confer a resistance to infection, resulting in a lower fatality rate among females [9]. Viral 
infection most commonly presents as influenza-like fever and dry cough which can 
progress to a more serious illness such as acute respiratory distress syndrome (ARDS) 
[20].  Additional symptoms include headache, diarrhea, dyspnea, hemoptysis, sputum 
production, and lymphopenia. It is important to note that gastrointestinal involvement 
such as diarrhea is more prominent SARS-CoV-2, as this was described in only a small 
percentage of patients infected with SARS-CoV and MERS-CoV. Gastrointestinal 
involvement provides another potential route of alternative transmission, as the virus 
could potentially be spread via urine sample or fecal matter. Poorer clinical outcomes are 
associated with multi-organ failure and eventual death. Symptoms appear after an 
approximate incubation time of 5 days, with death averaging around 14 days after 
symptom onset [20]. Research indicates that viral load peaks within 5-6 days of symptom 
onset. Severe cases progress to ARDS averagely 8-9 days following symptom onset. 
The pathogenesis of COVID-19 closely resembles that of SARS-CoV infection. An 
aggressive inflammatory response from the host immune system results in significant 
damage to the airways, indicating that disease severity is dictated by not only viral 
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infection but also the host response [9]. Interpretation of CT (computed tomography) 
scans typically reveals bilateral ground-glass opacities in sub-pleural regions of the lungs 
consistent with viral pneumonia. Infection with SARS-CoV-2 likely causes a localized 
and systemic immune response that leads to increased inflammation. Studies have 
revealed that patients show higher peripheral blood leukocyte numbers and increased 
levels of plasma pro-inflammatory cytokines such as IL2, IL7, GCSF MIP1α, and TNFα 
[20]. The release of these specific cytokines points to a T helper 1 (TH1) cell response, 
which is also the case in SARS-CoV and MERS-CoV [9]. The primary culprit of severe 
COVID-19 is aggressive pneumonia, followed by RNAaemia, ground-glass opacities, 
and cardiac injury [20]. ARDS caused by COVID-19 results in difficulty breathing and 
low blood oxygen levels. Because of this, patients are more likely to succumb to 
secondary infections. Additionally, ARDS may directly cause respiratory failure. This is 
the cause of death in 70% of fatal cases. The second most common cause of death is 
uncontrolled inflammation and symptoms of sepsis resulting from the cytokine storm, 
accounting for 28% of COVID-19-related deaths. This uncontrolled inflammation 
perpetrates multi-organ damage and subsequent failure of cardiac, hepatic, and renal 
systems [9].  
Investigation of SARS-CoV-2 viral pathogenesis via post-mortem biopsy has confirmed 
the inclusion of several extra-pulmonary system to be true. Biopsies taken from lung, 
liver, and heart tissue indicate overall systemic viral effects in cases of fatal COVD-19. 
Lung biopsy revealed bilateral diffuse alveolar damage (DAD) concurring with diffuse 
fibromyxoid exudates. Coinciding with findings of DAD, multiple biopsies included 
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hyaline membrane formation, desquamation of pneumocytes, and pulmonary edema, all 
of which are indicators of early phase ARDS. Multinucleated syncytial cells, type II 
pneumocyte hyperplasia, and prominent nucleoli were also observed and are all 
indicators of tenacious viral infection. Examination of liver illustrated moderate micro-
vesicular steatosis and mild lobular portal activity. However, there is no definitive 
evidence to support SARS-CoV-2 as the direct reason for observing these histologic 
features  [21]. Investigation of myocardium reveals interstitial mononuclear infiltrates as 
well as focal fibrosis and mild myocardial hypertrophy, which could be due to underlying 
comorbidities and not a direct result of viral effect. [21, 22].  It is reasonable to assume 
that pathological changes in other organs are secondary to the pro-inflammatory host 
response occurring in the lung, rather than a direct viral effect on these extra-pulmonary 
locations. Blood samples taken from deceased patients show a substantial reduction in 
levels of CD4 and CD8 cells with a hyperactivated status shown by high proportions of 
HLA-DR and CD38. Additionally, there was an increased concentration of the pro-
inflammatory CCR6+ Th17 in CD4 cells, as well as a high concentration of cytotoxic 
granules (perforin, granulysin, or both) within CD8 cells. These data imply that the 
manifestation of increased Th17 and cytotoxicity of CD8 cells resulting from T cell 
overactivation likely accounts for at least part of the severe immune injury in these 
patients [21]. Coagulation abnormalities and thrombosis are additional findings in some 
COVID-19 patients. The most common coagulopathy in COVID-19 patients is increased 
D-dimer concentration, followed by decreased platelet count and prolonged prothrombin 
time. These pathologic features create venous and thromboembolic complications within 
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the patient. Coagulopathy in cases of SARS-CoV-2 infection is believed to put patients at 
an increased risk for death, as a sudden decrease in plasma fibrinogen is seen shortly 
before death. Concentrations of antithrombin are lower in those who succumb to 
infection than in those who survive [23].  
Therapeutic options and vaccine development  
There is currently no standard of care for treating an individual with COVID-19. Though 
many individuals can make a full recovery without requiring medical intervention, some 
patients require mechanical ventilation and robust medical attention. On March 28, 2020, 
the United States Food and Drug Administration (FDA) cleared emergency authorization 
for the use of chloroquine and hydroxychloroquine, therapeutic agents that are approved 
to treat or prevent malaria. However, the FDA revoked emergency use authorization on 
June 15, 2020, stating that use of these agents is unlikely to be effective in treating 
COVID-19. Citing ongoing adverse cardiac events and other potential side effects, it was 
determined that the possible benefits of chloroquine and hydroxychloroquine did not 
outweigh the known risks [24].   
As of January 2021, there are over 300 COVID19 vaccine projects in place across the 
scientific community in all parts of the world. Over 40 of these studies are undergoing 
clinical assessment and 10 are in Phase III clinical trials [25]. On December 11, 2020, the 
FDA issued emergency use authorization (EUA) for the Pfizer-BioNTech COVID19 
Vaccine for the prevention of COVID19 in individuals 16 years of age and older [26]. 
Just one week later, on December 18, the FDA issued an EAU for a second COVID19 
vaccine, developed by Moderna, in individuals age 18 and older [27]. Each vaccine 
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requires two doses and reports efficacies over 94%, which greatly exceeds the 50% 
threshold previously enacted by the FDA [28]. Both the Pfizer and Moderna vaccines are 
mRNA-based, meaning they use mRNA (messenger RNA) to introduce an inactivated 
form of the virus to the host immune system. In both vaccines, mRNA that encodes for 
the viral spike protein is carried by liposomes. Once injected into the recipient, the host 
cells translate the mRNA to produce viral protein within the body. This allows the 
immune system to have a “preview” of the virus and an opportunity to confer immunity if 
ever exposed to the real thing. A caveat of mRNA vaccine technology is that it must be 
kept at -80°C [25] with the exception of the Moderna vaccine, which can be briefly stored 
at -20°C [7]. This creates a problem for non-first world nations that may not have access 
to the infrastructure and technology needed to appropriately store these vaccines. 
Additionally, the two-dose delivery method creates another layer of challenge as people 
could neglect to get the second dose, thus rendering the vaccine significantly less 
effective. On February 27, 2021, the FDA issued another EUA for the use of a single 
dose COVID-19 vaccine developed by Johnson & Johnson. The vaccine is authorized for 
use in individuals that are 18 years of age and older. Studies showed that this vaccine was 
66% effective in protecting against moderate-to-severe COVID-19 and 85% effective in 
preventing severe disease. This is a viral vectored vaccine that utilizes an adenovirus 
vector to carry the genetic code for the Spike protein into human cells that are then 
instructed to produce the viral protein. This is the same technology that Johnson & 
Johnson used for their Ebola vaccine, which has been authorized for use by the European 
Medicines Agency. The major plus-sides to this vaccine are that it is only one dose and it 
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does not require the elaborate cold-chain needed for mRNA vaccines. This means that the 
vaccine can be stored for up to 3 months at the temperature of a standard refrigerator. The 
caveat of this vaccine is that it has a lower efficacy rate than both Pfizer’s and Moderna’s 
vaccines [7].  There is currently a very limited supply of COVID-19 vaccines and they 
are not yet available to the general public. Law-makers on the national and state-wide 
level have grappled with how to appropriately allocate a relatively small supply of 
vaccines in a way that is both just and efficacious. Several organizations such as the 
CDC, the National Academies of Sciences, Engineering, and Medicine, and the Advisory 
Committee on Immunization Practices (ACIP), have released recommendations on 
vaccine allocation, all of which prioritize the vaccination of healthcare workers followed 
by phased distribution to vulnerable populations [29].   
Non-human primate models 
Non-human primates are typically ideal animal models for human disease due to the 
close phylogenetic relationship between species. Because of evolutionary likeness 
between primates, the immune systems of NHPs and humans often share a high degree of 
similarity when it comes to pathogen response. In many cases, viruses infect and replicate 
using the same mechanism in both NHPs and humans. Additionally, most reagents used 
to study viruses and the human immune response also cross react with NHP target 
molecules, rendering them an idyllic candidate to study viral infection, therapeutic safety, 
viral pathogenesis, vaccine efficacy, etc. [30]. In the context of SARS-CoV-2, NHP 
models have proven to be greatly variable in their practicality.  Rhesus macaques, a 
common NHP species used in scientific research, are shown to recapitulate only mild-to-
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moderate infection with SARS-CoV-2. Some macaques develop moderate pneumonia 
accompanied with weight loss, fever, and decreased appetite. Histologically, their lungs 
present with mild levels of edema, fibrin formation, necrosis, and immune cell infiltrate. 
Viral loads are highest in the nose and respiratory tract, with viral replication occurring 
predominantly in the lungs. Overall, the disease observed in Rhesus macaques is transient 
and moderate, similar to that seen in most humans [31]. Infection with SARS-CoV-2 has 
also been studied in the cynomolgus macaque, a close relative of the aforementioned 
rhesus macaque. Cynomolgus macaques achieve infection and viral replication, but do 
not present with clinical symptoms of COVID19. Histologic findings reveal lesions 
consistent with mild and moderate SARS-CoV-2 infection. Because they do not display 
clinical disease, cynomolgus macaques may be a good model of asymptomatic COVID19 
[32]. For the purposes of this research, we aimed to focus on severe COVID19 which is 
not observed in rhesus macaques or cynomolgus macaques. Severe COVID19 has 
sporadically been observed in African green monkeys (AGMs), the most widespread of 
all African monkey species. AGMs have shown to support viral replication and develop 
pronounced respiratory disease, separating them from rhesus macaque and cynomolgus, 
which support only limited viral replication and do not develop severe clinical disease 
[33]. In a study involving 8 AGMs of varying age, two animals developed ARDS with 
pathological lesions and disease similar to that seen in severe human cases. The other 6 
animals presented with mild clinical disease and pathological lesions consistent with mild 
COVID19 seen in humans and rhesus macaque. In the two animals that developed 
ARDS, thoracic radiographs revealed a diffuse alveolar pattern in the right lung fields 
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that were absent in radiographs from the prior day, highlighting rapid disease 
progression. Gross examination of the lungs revealed several lesions indicative of 
bronchointerstitial pneumonia such as severe consolidation and edema. Histopathologic 
findings were characterized by alveoli filled with fibrin, hemorrhage, and proteinaceous 
fluid. Consistent with the trend of diffuse alveolar damage, it was also noted that alveoli 
were multifocally lines with hyaline membranes and/or type II pneumocytes. Syncytial 
cells were observed in low-to-rare numbers. This study proves that, in some cases, AGMs 
can be a great tool in studying severe human COVID19. However, it cannot be known 
if/when a monkey will progress to severe clinical disease, thus creating a large caveat for 
this model. Because AGMs display a wide range of disease severity, they are useful in 
studies aiming to categorize all clinical manifestations [34]. 
From a purely scientific standpoint, NHPs are invaluable in studying human disease. 
However, there are many concerns that come along with using highly intelligent animals 
for the purpose of scientific exploration. In recent decades it has become increasingly 
controversial to employ primates in scientific research, primarily due to ethical and moral 
concerns. Because of this, the number of primate species being used in research has 
drastically decreased. Chimpanzees are the closest genetic relative to humans and were 
integral in studying the HIV and Hepatitis C viruses. However, ethical concerns and 
species endangerment have put an end to the use of chimpanzees as laboratory animals 
[30]. In addition to these concerns, research involving NHPs is a massive financial 
undertaking when compared to low-cost mouse and other small animal models.  
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Moreover, limited availability and variation among NHPs make it challenging to conduct 
studies with a large enough sample size to generate statistically sufficient data [35].  
Small animal models  
Due to the magnitude and widespread distribution of the SARS-CoV-2 pandemic, there is 
an unprecedented urgency for research surrounding this virus. Various barriers have been 
encountered by researchers attempting to study coronaviruses. Viruses like SARS-CoV-2 
exhibit a narrow species tropism, meaning that not all animals are readily infected with 
the virus. Traditionally available laboratory mice are not susceptible to infection with 
SARS-CoV-2, presenting a challenge for researchers looking to study the virus. A recent 
study tested infectivity in several strains of immunocompromised laboratory mice and 
concluded that the virus does not successfully replicate in the following mouse models: 
BALB/c, DBA/2J, Stat1-/- C57BL/6, AG129, and RAG1-/- C57BL/6. This solidifies the 
fact that murine ACE2 is unable to successfully interact with the spike protein of SARS-
CoV-2 [36]. Several transgenic mouse models have been developed for research 
surrounding SARS-CoV-2 and similar respiratory viruses. One such model is the Hfh4-
ACE2 transgenic mouse, which expresses human ACE2 under the Hfh4 (or Foxj1) 
promoter. This promoter drives expression of human ACE2 in ciliated cells of the 
respiratory tract epithelium and in the central nervous system (CNS). Once infected with 
SARS-CoV-2, mice show little clinical symptoms of disease, but only about 60% survive 
past day 5. Virus is detected in both the lung and brain, with high levels of virus in the 
brains of mice that succumbed to infection. Because lung function remains normal in 
these mice, there is reason to assume that death is a result of substantial neuroinvasion 
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rather than pulmonary disease [37]. Similarly, this trend of fatal neuroinvasion is also 
observed in k18-hACE2 transgenic mice. As previously mentioned, k18-hACE2 mice 
utilize the keratin-18 promoter to express human ACE2 in airway epithelial cells and 
some gastrointestinal cells, with a low level of expression in the brain. Studies involving 
K18 mice have reported this same trend of CNS localization followed by invariable 
fatality. Unlike the Hfh4-ACE2 mice, K18 mice do develop respiratory disease following 
infection with SARS-CoV-2. Disease in these animals is characterized by lung 
inflammation, serum cytokine and chemokine production, and high lethality [38]. 
Because transgenic mouse models susceptible to SARS-CoV-2 are currently in great 
supply, another method researchers have tried is transducing traditional laboratory mice 
with human ACE2. The BALB/c Adv-hACE2 model utilizes an adenoviral vector to 
transiently express hACE2 in BALB/c mice. Following infection with SARS-CoV-2, 
these mice express mild immune cell infiltration in peribronchiolar, perivascular, and 
alveolar locations. This model produces moderate disease with mild weight loss and lung 
pathology [36]. Recent scientific advances in CRISPR/Cas9 technology have also proved 
to be useful in the effort to produce SARS-CoV-2 animal models. One such method used 
CRISPR to knock-in hACE2 to terminate expression of murine ACE2 and stimulate 
expression of human ACE2. This renders the mice susceptible to infection with SARS-
CoV-2. Though no overt signs of clinical disease are observed, these mice produce 
histological profiles characteristic of interstitial pneumonia. H&E staining shows 
inflammatory cell infiltrate, alveolar septal thickening, and vascular system injury. Focal 
hemorrhage and additional epithelial lesions are also observed. These mice do not display 
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clinical manifestations and are able to recover from infection, making this a model of 
mild, non-lethal COVID-19 [39].   
Perhaps the biggest obstacle in establishing a small animal model of COVID-19 is the 
lack of available coronavirus animal models that elicit disease paralleled to disease 
observed in humans. As previously mentioned, ethical and financial hindrances make it 
difficult to study diseases in animals that are closely related to humans, such as non-
human primates [35]. For these reasons, small animal models are ideal when beginning 
research on a new virus. Though they are more ethically and financially appealing, rodent 
models must be altered in order to mimic human disease. Because of the immense 
diversity of pathogens, researchers must design models that are specific to each disease. 
Ideal animal models reflect clinical presentation, viral replication, and pathology 
observed in humans. In order to achieve this, the virus must share the same route of 
infection via comparable presence and distribution of viral receptors [35]. As this 
research study was designed to mimic viral pathogenesis in humans, our goal was to 
replicate key aspects of the disease exhibited in human infection. The lack of immune 
system similarity between humans and rodents creates the need for humanization 
techniques that permit human immune responses within a small animal vessel. The 
development of humanized mice traditionally begins with immunodeficient mice that are 
engrafted with human primary hematopoietic cells and tissues, with the goal of 
generating a functioning human immune system. Immunodeficiency is typically achieved 
by mutating the murine interleukin-2 (IL-2) receptor γ-chain, thus impairing development 
of natural killer (NK), B, and T cells.  Other techniques include knocking out the 
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recombination activating genes 1 and 2 (Rag1/Rag2), which severely impairs B and T 
cell responses as well as NK cell development. Deficiency of Rag genes prevents somatic 
recombination of immune cell receptors, thus inhibiting maturation of B and T cells. In 
addition to knocking out endogenous murine genes, researchers must also knock-in 
external stimulatory factors in order to achieve maturation and differentiation of myeloid 
progenitor cells. This is because murine stimulatory factors do not cross-react with 
human progenitor cells, which creates a non-viable mode of maturation for the 
humanized immune components [40].  The process of knocking-out murine stimulatory 
factors while simultaneously knocking-in human stimulatory factors permits the 
concurrent suppression of the endogenous mouse immune system with development of 
human immune system. Researchers can combine several different knockout and knock-
in gene techniques to achieve a highly specific model of murine immunocompromise that 
will promote human-like infection with a desired pathogen.    
Although useful in the evaluation of vaccine and therapeutic efficacy, animal models of 
SARS-CoV-2 to date have resulted in only mild to moderate pulmonary disease, lacking 
hallmarks of severe human infection. Though they are often a respectable model for 
human disease [41], pigs have proven to be impractical in the context of COVID-19. 
Previous studies on SARS-CoV reported successful experimental infection in pigs, with 
animals exhibiting viral RNA detection and seroconversion. Neither of these data are 
replicated in swine models of SARS-CoV-2. Primary in-silico data suggested that swine 
ACE2 should interact with SARS-CoV-2 spike protein, but several experimental attempts 
have shown that pigs are not readily susceptible to infection in vivo. Species that are 
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currently known to be naturally vulnerable to SARS-CoV-2 are of immediate interest 
since they don’t need to be strategically modified. Multiple experiments have shown that 
domestic cats (Felis catus) are susceptible to infection and are also able to transmit the 
virus to naïve cats. Both experimentally infected cats and contact-exposure cats 
seroconvert and present with viral replication in the upper and lower respiratory tracts 
and the GI tract. However, cats do not display clinical symptoms of COVID-19 and are 
also challenging to manage in biocontainment settings, thus rendering them an unlikely 
candidate as a translational animal model. In addition to cats, dogs, chickens, ducks, and 
minks have exhibited susceptibility to COVID-19 in experimental and natural disease but 
are not considered to be viable research models for a variety of reasons. Syrian hamsters 
are small mammals that are commonly used as models for respiratory viral infections 
such as adenovirus, influenza, and SARS-CoV. Human ACE2 and hamster ACE2 share a 
level of homology sufficient for successful interaction with SARS-CoV-2 spike protein, 
meaning that Syrian hamsters are also naturally susceptible to infection. Upon intranasal 
infection, hamsters present with mild-to-moderate disease with the most common clinical 
signs being weight loss and respiratory distress. Viral RNA is readily detected in the 
respiratory tracts of infected hamsters as well as lesser amounts in the small intestine. 
From a research standpoint, Syrian hamsters are a beneficial model for studying mild-to-
moderate SARS-CoV-2 infection and can be useful in studies focusing on transmission or 
therapeutics [42]. For the purposes of this research, we aimed to fill the need for an 
animal model that recapitulates severe COVID19, for which there are currently little-to-
no sufficient candidates.  
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Table 1. Comparison of various animal models of SARS-Cov-2 infection.  
Research models  
In this study, we implemented the use of an NRG mouse model derivative, the NRG-
Flk2-/-HLA-A2*-AAV/Flt3LG mouse. This specific model was chosen as a model of 
myeloid and NK-driven immunity. The base of this model is the NRG mouse, a non-
obese diabetic mouse deficient for RAG and IL-2 receptor gamma. These mice are 
immunocompromised with no mature murine B, T, or NK cells, as well as absence of 
complement, and defective dendritic cells and macrophages, further weakening their 
response to humanization. The mice are further altered to express the fetal liver kinase 
knockout mutation (Flk2). Flk2 (also called Flt3) is a cell surface receptor broadly 
expressed in early hematopoietic precursors in the bone marrow. Deficiency of this 
receptor impairs murine myeloid cell development, further permitting humanization 
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with human cells once the mice begin to express human immune system components. 
Once development of the NRG-Flk2-/- (NRGF) mice is achieved, mice are injected with 
Aav-Flt3LG that was produced in-vitro, in order to express human Flt3LG. This allows 
production of human myeloid cell lineages, with prior studies reporting significant 
expansion of CD33+ myeloid cells and dendritic cells in the spleen and bone marrow. 
Lastly, these mice transgenically express HLA-A2*0201, which allows human MHC 
presentation of pathogens. The resulting phenotype is the NRG-Flk2-/-HLA-A2*-
AAV/Flt3LG mouse, a model that depletes the murine immune system sufficiently to 
allow for successful humanization, thus permitting infection with human-specific 
pathogens. Prior studies have shown the success of this model by comparing mouse 
responses to the yellow fever vaccine. Compared to HIS/Fluc mice, the NRG model had a 
higher success rate at mimicking human response in each observed parameter [43]. We 
implemented this mouse model in conjunction with subcutaneous surgical implantation of 
human fetal lung xenografts as a platform to more closely mirror SARS-CoV-2 
pathogenesis in the context of a human immune system (dual engraftment). The resulting 
model is the HIS-NRGF-L mouse model with contralateral human fetal lung xenograft 
(fLX.) A representative diagram of the production of each model is shown in Figure 1. 
We used this model in conjunction with a standard NRG-L mouse engrafted with fLX 
(single engraftment) to ascertain the efficacy in each model. Our goal was to identify a 
model that consistently reproduces hallmark pathological lesions of severe COVID19 seen in 





Figure 1.  Schematic figure representing the process of mouse model development for 





All aspects of this study were approved by the Institutional Biosafety Committee and the 
office of Environmental health and Safety at Boston University prior to study initiation. 
All work with SARS-CoV-2 was performed in a biosafety level-3 (BSL3) laboratory by 
qualified personnel equipped with powered air-purifying respirators. Following 
euthanasia and necropsy, tissues were chemically inactivated for a minimum of 72 hours 
before being taken out of the BSL3 space. Upon certification of inactivation, the 
remaining work was done in a biosafety level-2 (BSL2) laboratory.  
Construction of NRGF and HIS-NRGF-L mice   
NOD Rag1-/- IL2Rgnull mice (NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ, obtained from the 
Jackson Laboratory, catalog number 007799). NRG-Flk2-/- (NRGF) mice (NOD.Cg-
Rag1tm1Mom Flt3tm1Irl Il2rgtm1Wjl/J) were generated as described previously at are available 
at The Jackson Laboratory (catalog number 033127). NRG, and NRGF mice were 
maintained at the Laboratory Animal Resource Center at Princeton University. All animal 
experiments described in this study were performed in accordance with protocols 
(number 1930) that were reviewed and approved by the Institutional Animal Care and 
Use and Committee of Princeton University.     
Generation of human lung tissue engrafted mice:  
Fetal lung tissues within a gestational age range of 18 to 22 weeks were obtained from 
Advanced Biosciences Resources (ABR, Alameda, CA). Upon receipt, fetal lung tissue 
was trimmed of visible connective tissue before processing the lung into cubes (3-5 
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mm/side) and placed into DMEM. NRG and NRGF mice engrafted with components of a 
human immune system (greater than 6 weeks of age) were anesthetized using isoflurane 
and placed in prone position. A midline incision was made along the skin of the upper 
back of the mouse. Forceps were used to create subdermal pockets on either side of the 
midline incision. A piece of lung was dried on a sterile drape and coated with Corning 
Matrigel Basement Membrane Matrix (product number 354234). Matrigel coated lung 
pieces were inserted into each of the subdermal pockets. Skin clips were used to secure 
the incision. Mice were used for infections 6-8 weeks following engraftment.  
Generation of AAV-Flt3Lg  
The pAB269 AAV backbone containing AAV2 ITRs was kindly provided by 
Markus Grompe (OHSU, Oregon). The plasmid was digested with PacI/MluI HF. The 
FLT3 was PCR amplified from pAL119-FLT3L (Addgene, item #21910), and the TBG 
was amplified from pX602-AAV-TBG::NLS-SaCas9-NLS-HA-OLLAS-
bGHpA;U6::BsaI-sgRNA (Addgene, item #61593). The FLT3, TBG, and BGH PCR 
products had 15 bp of overlapping sequence with adjacent inserts and backbone and were 
assembled with In-Fusion (Takara, Mountain View, CA) to create the final construct.   
AAV-293 cells (Agilent, Santa Clara, CA) at 50% confluency in 15 cm dishes were 
transfected via the calcium phosphate method with 22.5 ug XR8 (NGVB, Indianapolis, 
IN), 7.5 ug pHelper (Agilent, Santa Clara, CA), 7.5 ug of pAB269-TBG-FLT3 LG-BGH 
per plate. Media was collected every 24 hours for 72 hours total. After 72 hours, the 
media was treated with a 5x solution of 40% PEG8000 and 2.5 M NaCl to precipitate the 
AAV for two hours at 4C before being spun down at 4300 x g for 20 minutes. Cells from 
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plates were scraped, washed with PBS, and resuspended in hypotonic buffer (10 mM 
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.35 mg/ml spermine) on ice for 10 min before 1 
ml restore buffer (62.5% sucrose wt/vol in hypotonic buffer) was added. Cell membranes 
were sheared in a 15 ml Kontes dounce homogenizer and nuclei were spun down at 500 x 
g for 10 min. AAV from PEG precipitate was resuspended in 6 ml high salt buffer (2.5 
mM KCl, 1 mM MgCl2, 1 M NaCl in PBS) and added to nuclei that had been 
resuspended in 1 ml low salt buffer (2.5 mM KCl, 1 mM MgCl2, in PBS). Lysate was 
treated with 250 units of Benzonase (Sigma) at 37C for 30 min and then spun at 4300 x g 
for 30 min before being loaded onto an iodixanol gradient. AAV was spun at 38,000 rpm 
in an SW41 rotor for 3 hours at 16C. AAV was collected from the 40% iodixanol layer 
and buffer was exchanged to AAV storage buffer (PBS with 35 mM NaCl, 
0.002% pluronic F-68, 5% glycerol) in a 100 MWCO centrifugal filter column 
(Millipore). Samples were analyzed via silver stain to check purity and qPCR to 
quantify.   
SARS-CoV-2 NanoLuciferase virus stock.  
A recombinant SARS-CoV-2 NanoLuciferase virus (Xie X. et al, 2020 Nature Comm.) 
was propagated on Vero E6 cells. Vero E6 cells were plated one day prior to virus 
passaging and infected with 10 uL of SARS-CoV-2 NanoLuciferase virus in 5 mL 
of OptiMEM media (Gibco, catalog #51985034). 72 hours post infection cell supernatant 
was collected and filtered through a 0.45 uM filter. Filtered supernatant was concentrated 
by ultracentrifugation (Beckman Coulter, catalog #C14292) with 20% (w/v) sucrose TNE 
solution (50mM Tris, 100nM NaCl, 1mM EDTA, pH=7.4) for 2 hours at 25,000 x g at 
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4C. Concentrated virus was resuspended in 1X PBS. Viral titer was determined by plaque 
assay.  
H&E histopathological evaluation 
5µm sections were prepared from FFPE (formalin-fixed, paraffin-embedded) lung tissue 
and transferred to glass slides. Tissue samples were deparaffinized and stained with 
hematoxylin and eosin (H&E) using a combined Leica Autostainer-coverslipper unit 
ST5010-CV5030 (Leica Microsystems, Wetzlar, Germany). Brightfield images were 
captured using a Mantra 2.0TM microscope (Akoya Biosciences, Marlborough, MA). 
Images were analyzed by Dr. Nicholas Crossland, a board-certified veterinary 
pathologist, in order to determine key pathological features within the tissues. Each of the 
histologic features were scored between 0 to 3, dependent on the criteria outlined in 
Table 2. The entire xenograft was examined at 200x total magnification. 
Acknowledging that histopathologic features predominate in pseudo glandular and 
canalicular phenotypes, analysis was restricted to these subsections using the following 
criteria: 0 = not present, 1 = found in <5% of HPF, 2 = found in >5% but <25% of HPF, 3 









Table 2. Lung injury ordinal scoring in SARS-CoV-2 infected mice  
Parameter  0  1 (>5%)  2 <25%  3 >25%  
Syncytial cells   None  Observed  N/A  N/A  
Hyaline 
Membrane  
None  Observed                                                           
Neutrophils in 
airspaces  
None  1-5  >5<10  >10  
Airspace 
hemorrhage  
None  Mild  Moderate  Severe  
Interstitial and/or 
airspace edema  
None  Mild  Moderate  Severe  
Desquamated 
pneumocytes  
None  Mild  Moderate  Severe  
Intra-airspace 
necrosis  
None  Mild  Moderate  Severe  
Capillary fibrin 
thrombi  
None  Mild  Moderate  Severe  
Intermediate to 
large vessel fibrin 
thrombi  





None  Observed                                                          
N/A-not applicable  
Table 2. Lung injury ordinal scoring in SARS-CoV-2 infected mice 
Statistical analysis of brightfield histopathology  
The non-parametric Kruskal Wallis test was used to evaluate the ordinal histopathologic 
scoring data. The test was performed to determine the presence of statistical significance 
between unmatched groups: control, 2DPI, and 7DPI. The two-stage linear step-up 
procedure of Benjamini, Krieger, and Yekutieli was applied with an α rate of 0.05 and a 
priori to correct for multiple comparisons. GraphPad Prism 9.0.1 was used for all 
statistical analyses and formulation of graphical depictions of results.  
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Fluorescent multiplex immunohistochemistry (mIHC) with tyramide signal 
amplification (TSA) 
Fluorescence mIHC with TSA was conducted using Akoya Bioscience’s Opal 
Dye Kit. Automated mIHC was run on a Ventana Discovery Ultra (Roche, Basel, 
Switzerland). Before multiplex-IHC was performed, each antibody was individually 
optimized using a single-plex-IHC assay using an appropriate positive control tissue. 
Optimizations were performed to determine ideal primary antibody dilution, sequential 
order of antibody development, assignment of each primary antibody to an Opal 
fluorophore, and fluorophore dilution. Once an optimal protocol was established, 5µm 
tissue sections were cut from FFPE fetal lung xenograft mice infected with SARS-CoV-
2. An overview of the mIHC workflow is provided in Figure 2. Antibodies utilized in 
5plex 6 color (DAPI counterstained) analysis included: (Panel 1) SARS-CoV-2 Spike 
protein, CD68 a monocyte/macrophage marker, CD61 a platelet marker, Pro-Surfactant 
Protein-C an alveolar type II pneumocyte marker, and CD31 an endothelial marker or 
(Panel 2) SARS-CoV-2 Spike protein, human specific CD68 a monocyte/macrophage 
marker, human specific CD3e a pan T cell marker, human specific CD8 a cytotoxic T cell 
marker, and human specific CD20 a B cell marker. Antibody targets were selected based 
on pathological lesions of interest pertaining to COVID-19 infection. Optimized 




Figure 2. Workflow of fluorescent multiplex IHC 
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Table 4. Optimized conditions for mIHC panel 2. 
Whole slide scanning and digital image analysis of mIHC  
Fluorescently labeled slides were imaged using either a Mantra 2.0TM  or Vectra Polaris 
TM  Quantitative Pathology Imaging System (Akoya Biosciences). To maximize signal-to-
noise ratios, images were spectrally unmixed using a synthetic library specific for the 
Opal fluorophores used for each assay and for DAPI. Furthermore, an unstained fLX 
section was used to create an autofluorescence signature that was subsequently removed 
from whole-slide images using InForm software version 2.4.8 (Akoya Biosciences). A 





Figure 3. Whole slide scan of bilateral fetal lung xenografts taken from an NRG-L 
mouse. The top tissue is an uninfected control, and the bottom tissue is from 2DPI with 
SARS-CoV-2.  
 
Image analysis of multiplex immunohistochemistry  
Digitized whole slide scans were analyzed using the image analysis software HALO 
(Indica Labs, Inc., Corrales, NM). Slides were manually annotated to select regions of 
interest, excluding accessory skin and adipose tissue and including only the fetal lung 
xenograft. Visualization threshold values were adjusted in viewer settings to reduce 
background signal and fine-tune visibility of markers within each sample. Quantitative 
outputs were obtained using the Area Quantification (AQ) module, which reports total 
area of immunoreactivity of a specified parameter within a region of interest. Values are 
given as a percentage of total tissue area analyzed. Minimum dye intensity thresholds 
were established using the real-time tuning field of view module in order to accurately 
detect positive immunoreactivity. For panel 1, AQ was performed to determine 
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percentages of SARS-CoV-2 Spike, CD31 and CD68+ immunoreactivity within each 
biopsy. A visual example of an AQ output using HALO™ is shown in Figure 4. For 
panel 2, we employed the HALO Highplex (HP) module which allows for simultaneous 
analysis of multiple fluorescent markers within a cellular compartment. Cells are 
identified using DAPI to segment individual nuclei. Minimum cytoplasm and membrane 
thresholds are set for each dye to detect positive staining within a cell. Parameters are set 
using the real-time tuning mechanism that was tailored for each individual biopsy based 
on signal intensity. Phenotypes are determined by selecting inclusion and exclusion 
parameters relating to stains of interest. For panel 2, we used the following phenotypes: 
CD3+CD8- (helper T-cells), CD8+ (cytotoxic T-cells), CD20+ (B-cells), and CD68+ 
(macrophages). Outputs are shown in Figure 5 and Figure 6. The algorithm produces a 
quantitative output for each cell phenotype as well as total cells, total area analyzed, etc. 
For our analysis, we used cells/µm2. The AQ module was also used in panel 2 for 




Figure 4. Visual output of area quantification module in HALO™. (A) Raw image with 
DAPI in grey and Spike immunoreactivity in yellow. (B) Correlating output of Spike AQ 
shown in yellow.  
 
 
Figure 5. Visual output of T-cell phenotyping in HALO™. DAPI – grey, CD3e – cyan, 





Figure 6. Visual output of B-cell and macrophage phenotyping in HALO™. DAPI – 
grey, CD20 – green, CD68 - red. (A) Raw Image. (B) Cell phenotyping visual output.  
 
Statistical analysis of multiplex immunohistochemistry 
The non-parametric Kurskall-Wallis test was used to analyze area quantification and cell 
phenotyping outputs of mIHC panels 1 and 2. The test was performed to determine the 
presence of statistical significance between unmatched groups: control, 2DPI, and 7DPI. 
For area quantification, the test was used to determine significance in the % area of 
SARS-CoV-2-Spike antigen in each biopsy. For panel 2, this test was used to determine 
if there was statistical significance in immune cell quantity between groups. The two-
stage linear step-up procedure of Benjamini, Krieger, and Yekutieli was applied with an α 
rate of 0.05 and a priori to correct for multiple comparisons. GraphPad Prism 9.0.1 was 
used for all statistical analyses and formulation of graphical depictions of results. 
Flow cytometry 
Between 5x10^5 – 1x10^6 cells were used for flow cytometry staining. Cells were added 
to a 1.5 mL tube and centrifuged at 300 x g for 5 minutes at 4C. The cell pellet was 
resuspended in Fc block mix of 22.5 uL FACS buffer and 2.5 uL of FcX (Biolegend; 
#422302) and incubated for 10 minutes at room temperature. After blocking 25 uL of 
antibody cocktail containing hCD3, hCD20, hCD16, hHLA-DR, hCD45, hCD8, hCD4, 
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hCD33, hCD45RA, hCD56, hCD14, mCD45, and LIVE/DEAD viability was added to 
each sample and incubated in the dark for 30 minutes at 4C. After staining 1 mL of FACS 
buffer was added to each sample, samples were centrifuged at 300 x g for 5 minutes, 
washed with 1 mL FACS buffer, centrifuged at 300 x g for 5 minutes, and then fixed in 
200 uL 4% paraformaldehyde (PFA) for 30 minutes. After fixation cells were washed 
twice with 1 mL FACS buffer, resuspended in FACS buffer, and stored protected from 
light at 4C prior to analysis. Analysis was performed on a flow cytometer and analyzed 
with FlowJo Software.   
 Tissue Processing and RNA Extracations 
Tissues were collected from mice and placed in 600 mL of RNAlater (Sigma – Aldrich; 
# R0901500ML) and stored at -80°C. For processing, 20 – 30 mg of tissue was taken and 
placed in into a 2 mL tube with 600 mL of RLT buffer with 1% b – mercaptoethanol and 
a 5 mm stainless steel bead (Qiagen; #69989). Tissues were then dissociated using a 
Qiagen TissueLyser II (Qiagen; Germantown, MD) with the following cycle; two-minute 
dissociation at 1800 oscillations/minute, one-minute rest, two-minute dissociation at 1800 
oscillations/minute. Samples were then subject to centrifugation at 13,000 rpm for 10 
minutes and supernatant was transferred to a new 1.5 mL tube. RNA extractions were 
performed using a Qiagen RNeasy Plus Mini Kit (Qiagen #74134), according to the 
manufacturer’s instructions, with an additional on-column DNase treatment (Qiagen; 
#79256). RNA was eluted in 30 uL of RNase/DNase free water.  
SARS-CoV-2 Reverse Transcription-qPCR 
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To determine SARS – CoV- 2 RNA copies RT – qPCR for SARS – CoV - 2 E protein 
was performed using a One-Step Taqman – based system. Briefly, a 20 uL reaction 
mixture containing 10 uL of Quanta qScript™ XLT One-Step RT-qPCR ToughMix® 
(VWR; #76047-082), 0.5 uM Primer E_Sarbeco_F1 
(ACAGGTACGTTAATAGTTAATAGCGT), 0.5 uM Primer E_Sarbeco_R2 
(ATATTGCAGCAGTACGCACACA), 0.25 uM Probe E_Sarbeco_P1 (FAM-
ACACTAGCCATCCTTACTGCGCTTCG-BHQ1), and 2 uL of total RNA was subject 
to One-Step RT – qPCR using Applied Biosystems QuantStudio 3 
(ThermoFisher Scientific), with the following cycling conditions; reverse transcription 
for 10 minutes at 55°C and denaturation at 94°C for 3 min followed by 45 cycles of 
denaturation at 94°C for 15 seconds and annealing/extension at 58°C for 30 seconds. Ct 
values were determined using QuantStudioTM Design and Analysis software V1.5.1. 
Calculations for RNA copies/mL were determined using a SARS – CoV – 2 E RNA 
standard.  
Transmission Electron Microscopy 
 Tissue samples were fixed for 72 hours in a mixture of 2.5% Glutaraldehyde and 2% 
formaldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Samples were then washed in 
0.1M cacodylate buffer and postfixed with 1% Osmiumtetroxide (OsO4)/1.5% 
Potassiumferrocyanide (KFeCN6) for 1 hour at RT.  After washes in water and 50mM 
Maleate buffer pH 5.15 (MB) the samples were incubated in 1% uranyl acetate in MB for 
1hr, washed in MB and water, and dehydrated in grades of alcohol (10min each; 50%, 
70%, 90%, 2x10min 100%). The tissue samples were then put in propyleneoxide for 1 hr 
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and infiltrated ON in a 1:1 mixture of propyleneoxide and TAAB Epon (TAAB 
Laboratories Equipment Ltd, https://taab.co.uk). The following day the samples were 
embedded in fresh TAAB Epon and polymerized at 60C for 48 hrs. 
Semi-thin (0.5um) and ultrathin sections (50-80nm) were cut on a Reichert Ultracut-S 
microtome. Semi-thin sections were picked up on glass slides and stained with Toluidine 
blue for examination at the LM level to find affected areas in the tissue. Ultrathin sections 
from those areas were picked up onto formvar/carbon coated copper grids, stained with 
0.2% lead citrate and examined in a JEOL 1200EX transmission electron microscope. 






Microscopic Characterization of the fLX Landscape 
Ten to fifteen-week-old male and female NOD-Rag1-/-IL2RγNULL (NRG-L) mice were 
surgically implanted subcutaneously with two pieces of fLX, one on each side of the 
animal’s thoracic body wall. Following engraftment, all animals were healthy and did not 
demonstrated evidence of graft rejection. Ten to fifteen weeks post engraftment, animals 
displayed large and macroscopically noticeable fLX on both side of their body, with a 
diameter of 8mm to 1.5cm (Figure 7). Macroscopic and histological analysis illustrated 
interstitial infiltration of fLX by murine blood vessels with retention of human 
vasculature (Figure 8). Cells appeared histologically normal with no evidence of 
degeneration and/or necrosis that would be suggestive of tissue ischemia/hypoxia. fLX 
were characterized by sporadic regions of conducing zone differentiation evidenced by 
the presence of bronchioles and hyaline cartilage, as well as more abundant and 
heterogenous stages of respiratory zone development, which included combinations of 
pseudo glandular, canalicular, and saccular phenotypes (Figure 9). These primordial 
respiratory stages of lung development are consistent with those previously described for 
normal fetal lung development [44]. Maturation of lung parenchyma was characterized 
by transitioning of epithelium from ciliated columnar and/or cuboidal epithelium to 
squamous epithelium (Figure 9), retraction of stromal mesenchyme, and organization of 
capillaries to parallel adjacent epithelium ultimately forming discrete septa. Different 
stages of fetal lung maturation were associated with differential expression of ACE2, 
Prosurfactant Protein C (pro-SPC) (AT2 pneumocyte differentiation marker), and human 
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specific CD31 (blood vessel marker). Regions with a more immature phenotype (pseudo 
glandular) were associated with the highest immunoreactivity for these three antigens, 
while more mature stages of fetal development (canalicular and saccular) had decreased 
expression. In regions of respiratory zone differentiation, ACE2 expression was primarily 
restricted to cells concurrently expressing proSP-C, consistent with alveolar type 2 (AT2) 
pneumocyte origin. ACE2 was also observed along the apical surface of bronchiole 
epithelium, which lacked proSP-C expression. Previous studies employing fLX-engrafted 
mice to model intra-lung responses to viral infection never reported, or took into 
consideration in their interpretation, the presence of a fLX-resident hematopoietic 
compartment. Strikingly, flow cytometry analysis and single-cell RNA sequencing 
demonstrated a large presence of hematopoietic lineages in the fLX of NRG-L mice 15-
20 weeks post engraftment.  
 
Figure 7. Bilateral fetal lung xenografts (fLX) subcutaneously implanted remain viable 
in NRG mice, with recruitment of subcutaneous murine blood vessels into the fLX, 





Figure 8. Subcutaneous engraftment of fetal lung xenografts (fLX) in NRG mice results 
in integration of murine and human blood vessels. (A) Integration of murine and human 
blood vessels at the interface of murine subcutis and fLX (black hash line). (B) Both 
human and murine blood vessels are present within the fetal lung xenograft interstitium. 
Purple (murine CD31) and brown (human CD31) duplex IHC, 200x (left, bar=100um), 
400x total magnification (right, bar=50um).  
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Figure 9. Fetal lung xenografts contain heterogenous stages of lung maturation and 
differentiation affiliated with differential expression of ACE2 (host receptor for SAS-
CoV-2), Prosurfactant Protein C (proSPC-Alveolar type II pneumocyte differentiation), 
and CD31 (endothelium-human specific). (A-B) Pseudoglandular phenotype, columnar to 
cuboidal pneumocytes with high expression of ACE2 and proSPC, forming glandular like 
structures supported by prominent mesenchymal stroma with high vascular density. (C-
D) Canalicular phenotype, low cuboidal pneumocytes with moderate sporadic expression 
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of ACE2 and proSPC, retraction of mesenchymal stroma, decreased vascular density, and 
formation of coalescing airspaces with loss of distinct glandular like structures. (E-F) 
Saccular phenotype, further enlargement of airspaces lined by squamous epithelium with 
low to moderate expression of ACE2 and proSPC, formation of distinct septal like 
structures, and low vascular density. (G-H) Bronchiole differentiation, columnar to 
pseudostratified ciliated epithelium with apical ACE2 expression and absence 
of proSPC. A, C, E, & G-Hematoxylin and Eosin (H&E), total magnification 100x, 
B, D, F, & H- fluorescent multiplex immunohistochemistry (mIHC),total  magnification 
200x. DAPI – grey, ACE2 – magenta, pro-SPC – teal, human-CD31 – green.  
 
Successful Replication of SARS-CoV-2 in Infected NRG-L fLX 
We first aimed to extensively characterize SARS-CoV-2 infection in NRG-L mice. Ten 
to fifteen weeks post engraftment, NRG-L were inoculated subcutaneously with a SARS-
CoV-2 clinical isolate directly into the fLX, at a viral dose of either 10^4 or 10^6 plaque 
forming unit (PFU). Although we inoculated both grafts in most NRG-L mice, some 
animals were inoculated only through a single fLX, in order to evaluate the possibility of 
graft-to-graft viral spread through viremia. The non-inoculated grafts from infected 
animals are hereon referred to as “contralateral” grafts. As expected, over the course of 
infection, NRG-L mice did not display any signs of overt clinical disease, maintained 
their weight, and had no significant alternations in core body temperature. NRGL-L mice 
were euthanized at 2- and 7-days post-infection (DPI), with gross abnormalities observed 
in inoculated fLX at both time points. Lesions were characterized by well demarcated 
areas of red and pale-tan discoloration (Figure 10). This contrasted with uninfected 
contralateral fLX, which had a white homogenous appearance (Figure 10). 
Immunoreactivity to SARS-CoV-2 nucleocapsid (N) in inoculated fLX was observed in a 
dose dependent manner, with more abundant viral antigen observed in fLX inoculated 
with the 10^6 dose (Figure 11).  SARS-CoV-2 N immunoreactivity was not observed in 
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contralateral uninoculated fLX, suggesting absence of fLX to fLX transfer through the 
blood. Lastly, SARS-CoV-2 N immunoreactivity was not observed in the 10^4 dose at 
day 7, suggesting that at this dose fLX are capable of clearing infection, while SARS-
CoV-2 N antigen was observed in all fLX at 7 dpi with the 10^6 dose. RT-qPCR 
quantification of viral RNA (E coding sequence) was consistent with 
immunohistochemistry findings. Although RT-qPCR suggested that viral RNA was 
present in contralateral uninoculated fLX, this was never associated with 
immunoreactivity. By correlating viral load with N immunoreactivity for each fLX, we 
established that viral loads superior to a threshold of 10^7 – 10^10 viral RNA copies/mg 
tissue were indicative of productive infection.   
Figure 10. SARS-CoV-2 inoculated fetal lung xenografts illustrate macroscopic evidence 
of pathology. (A) Uninoculated control, soft doughy, homogenous pale tan to white fLX. 
(B) 7 days post SARS-CoV-2 infection, areas of red (black arrow) and pale tan to yellow 
(asterisk) were histologically confirmed to represent hemorrhage and coagulative 




Figure 11. SARS-CoV-2 inoculation in fetal lung xenografts (fLX) displays dose 
dependent worsening of histologic phenotypes and increased viral antigen. (A-B) 10^4 
PFU SARS-CoV-2 inoculum, at 2 days post-infection (DPI) SARS-CoV-2 nucleocapsid 
(N) is found in low numbers of cuboidal epithelial cells, with little to no residual N 
antigen at 7 DPI. (C-D) 10^6 PFU SARS-CoV-2 inoculum, at 2 DPI SARS-COV-2 is 
found in moderate numbers of cuboidal epithelial cells with formation of syncytial cells 
(black arrows). At 7 dpi, SARS-CoV-2 N is routinely observed within intra-airway 
necrotic debris consistent with denuding and necrosis of pneumocytes. Brown (SARS-
CoV-2 N) IHC, total magnification 400x, bar=50um.  
 
Semi-Quantitative Histopathologic Analysis 
To capture the heterogeneity and severity of histologic phenotypes observed in SARS-
CoV-2 infected fLX, we developed a semi-quantitative ordinal scoring system (Table 2). 
Specific scoring criteria and individual animal data are found in Table 5. Positively 
correlated with viral load and SARS-CoV-2 N IHC data, mean cumulative scores in 10^6 
inoculated animals were 1.76-fold higher on 2 dpi and 2.22 on 7 dpi compared to 10^4 
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(Figure 12). Taken together, we elected to pursue all subsequent analysis of SARS-CoV-
2 infected fLX using the 10^6 dose due to worsening disease outcomes. Histopathologic 
findings were observed in all SARS-CoV-2 inoculated fLX and predominated in 
immature stages of fetal lung (pseudo glandular and canalicular phenotypes). Severity of 
lesions was variable, ranging from mild focal to severe generalized disease. Examination 
of serial sections confirmed that histologic lesions predominated in areas with SARS-
CoV-2 N immunoreactivity. At 2 DPI, affected terminal airspaces (we avoided the use 
alveoli acknowledging fLX were not fully developed to warrant use of this term) were 
infiltrated by neutrophils, with variable amounts of hemorrhage, edema, fibrin, denuded 
epithelial cells, rare scattered karyorrhectic debris, erythrophagocytosis and 
hemosiderosis (Figure 13). Sporadic syncytial cells lined and/or were located freely 
within airspaces (Figure 13). In areas of severe neutrophilic inflammation, increased 
numbers of mitotic figures were observed in pneumocytes supportive of active 
regeneration, with concurrent pneumocyte degeneration represented by cytoplasmic 
swelling and vacuolation. Lung interstium was expanded by clear space (edema), with 
low numbers of neutrophils and macrophages. Capillaries and (Figure 13) intermediate 
sized arterioles and arteries were multifocally occluded by fibrin thrombi, which in rare 
instances was affiliated with regional coagulative necrosis (Figure 13). At 2 DPI SARS-
CoV-2 N immunoreactivity was observed predominantly in the cytoplasm of cuboidal 
epithelial cells interpreted as AT2 pneumocytes, syncytial cells, and admixed within 
necrotic debris in airspaces. At 7 DPI, similar features as described at 2 DPI were 
observed; however, airspaces were more frequently filled with abundant necrotic cellular 
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debris as evidence by karyorrhexis, which was rarely observed at 2 DPI.  A distinct 
hyaline membrane was observed lining pneumocytes in one 7 DPI fLX (Figure 13). 
Cumulative histology scores at both 2 (p=0.0010) and 7 dpi (p=0.0002) were increased 
when compared to uninoculated fLX. Neutrophil influx (2 dpi, p≤0.0001; 7 dpi, 
p≤0.0001), intra-airspace necrosis (2 dpi, p =0.0038; 7 dpi, p =0.0006), capillary fibrin 
thrombi (2 dpi, p =0.0098; 7 dpi, p =0.0015), and presence of syncytial cells (2 dpi, p 
=0.0006; 7 dpi, p =0.0097) were the most significant independent observations that 
contributed to the increased cumulative score. Together these findings indicate that fLX 
inoculated with SARS-CoV-2 faithfully recapitulate several features of diffuse alveolar 
damage (DAD) described in severe COVID-19, including epithelial degeneration and 
necrosis, neutrophil influx, microthrombi, edema, and hemorrhage with dose dependent 
severity.  
 
Table 5. NRG-L fLX individual animal histopathology summary data. 

































654 32 L 0 0 0 1 1 0 0 0 1 0 3
657 35 R 0 0 0 0 1 0 0 0 0 0 1
658 36 L 0 0 0 0 1 0 0 0 1 0 2
59 54 L 0 0 0 0 0 0 0 0 1 0 1
62 55 R 0 0 0 0 1 1 0 0 1 0 3
514 57 L 0 0 0 1 1 1 0 0 0 0 3
316 64 L 0 0 0 1 1 2 0 1 0 0 5
398 110 R 0 0 0 1 1 1 0 0 0 0 3
61 52 R 0 0 1 2 2 2 1 1 1 0 10
59 54 R 1 0 1 2 2 2 2 3 3 1 17
62 55 L 1 0 1 2 1 1 2 2 2 0 12
514 57 R 1 0 1 3 2 2 1 1 2 0 13
517 58 L 1 0 0 1 0 1 0 1 1 0 5
310 27 L 1 0 1 1 1 1 1 0 0 0 6
657 35 L 1 0 3 2 2 2 3 1 0 0 14
585 107 L 1 0 3 1 1 2 2 1 2 0 13
673 108 R 1 0 1 2 2 1 1 0 0 0 8
398 110 L 1 0 2 2 1 1 1 2 2 0 12
395 112 L 1 0 2 2 2 1 2 1 2 0 13
394 113 L 1 0 2 1 2 1 2 1 3 0 13
658 36 R 1 1 2 2 1 2 3 2 2 0 16
52 53 L 1 0 2 2 3 2 1 3 3 0 17
52 53 R 1 0 2 2 2 2 1 3 3 0 16
316 64 R 0 0 2 1 1 1 1 1 1 0 8
42 60 L 0 0 1 2 2 2 2 1 1 0 11
42 60 R 0 0 1 1 1 2 0 1 1 0 7
54 56 L 1 0 3 2 3 3 3 3 3 1 22

































Figure 12. Cumulative score of NRG-L mice given 10^4 vs 10^6 PFU inoculation dose 






Figure 13. Representative histopathologic phenotypes in human fetal lung xenografts 
(fLX) infected with SARS-CoV-2 in NRG-L mice. (A) Syncytial epithelial cells (black 
arrows) and interstitial edema (asterisks). (B) Denuded epithelium (black arrows). (C) 
Hyaline membrane (black arrows). (D) Coagulative necrosis (left of hash line), adjacent 
to viable fLX  (right of hash line). (E) Fibrin thrombi occluding intermediate sized blood 
vessels (black arrows), with interstitial edema (asterisks). (F) Fibrin thrombi occluding 
interstitial capillaries (black arrows). (G) Neutrophil accumulation within airspaces 
(within black hash lines). (H) Accumulation of necrotic debris within airspaces 
(asterisks). (I) Accumulation of erythrocytes with airspaces (i.e., 






Figure 14. Statistical analysis of histopathologic criteria among NRG-L mouse fetal lung 
xenografts (control n=8, 2DPI n=12, 7DPI n=8) with asterisks indicating level of 
statistical significance. (A) Syncytial cells significant between control vs 2DPI 
(p=0.0002) and control vs 7DPI (p=0.0394). (B) Intra-airspace neutrophils significant 
between control vs 2DPI (p=0.0032) and control vs 7DPI (p=0.0003). ( C) Airspace 
hemorrhage significant between control vs 2DPI (p=0.0021) and control vs 7DPI 
(p=0.0042). (D) Edema significant between control vs 7DPI (p=0.0228). (E) Denuded 
pneumocytes significant between control vs 7DPI (p=0.0016) (F) Intra-airspace necrosis 
significant between control vs 2DPI (p=0.0022) and control vs 7DPI 
(p=0.0023). (G) Capillary fibrin thrombi significant between control vs 2DPI (p=0.0275) 
and control vs 7DPI (p=0.0004). (H) Intermediate to large vessel fibrin thrombi 
significant between control vs 7DPI (p=0.0138). (I) Coagulative necrosis not statistically 
significant between groups. (J) Cumulative score significant between control vs 2DPI 
(p=0.0026) and control vs 7DPI (p=0.0002) 
 
Ultrastructural Findings, Transmission Electron Microscopy  
To further corroborate histologic findings and more definitely characterize what cell 
types were supporting productive viral infection we performed transmission electron 
microscopy to characterize ultrastructural findings affiliated with this model. At 2 DPI, 
clusters of virus particles were observed in epithelial cells lining airspaces that contained 
 
51 
lamellar bodies consistent with alveolar type 2 (AT2) pneumocytes.  Virions were also 
observed free within affected airspaces and phagocytosed by macrophages (Figure 15). 
Virus particles within AT2 pneumocytes were observed at various stages of maturation 
and often confined to double membrane bound vesicles (DMVs), with morphology and 
particle size consistent with previously described coronaviruses. At 7 DPI, airspaces were 
filled with abundant necrotic cellular debris including lamellar bodies, erythrocytes, 
neutrophils and denuded AT2 pneumocytes, which were occasionally undergoing 
apoptosis as indicated by the presence of pyknotic nuclei (Figure 16). Infected AT2 
pneumocytes had large regions of virus induced membrane alterations, which included 
double-membrane spherules (DMS) and DMVs, with variable stages of virus particle 
maturation (Figure 17). Mature virus particles contained characteristic black dots 
representative of cross-sections through the SARS-CoV-2 N protein, with faint Spike 
protein coronal surface projections sometimes visible (Figure 18). Blood vessels 
contained aggregates of platelets (Figure 19) with several small to intermediate sized 
arteries occasionally occluded by fibrin thrombi (Figure 20). Altogether, these data are 





Figure 15. Virions free within the airspace phagocytized by a neighboring macrophage 




Figure 16. Airspace filled with necrotic cellular debris including lamellar bodies, 
denuded type II pneumocytes undergoing apoptosis characterized by condensation of 






Figure 17. Virus particles at various stages of maturation within the cytoplasm of a type 
II pneumocyte as indicated by the presence of lamellar bodies. Virus particles are both 




Figure 18. Cluster of mature virus particles with radiating spikes and aggregates of 
nucleocapsid protein contained within a double membrane-bound vesicle. Neighboring 








Figure 20. Occlusion of vascular lumen by polymerized fibrin. Adjacent endothelium is 
abruptly absent, suggestive of necrosis.  
 
mIHC Digital Analysis on NRG-L mice 
Fluorescent multiplex immunohistochemistry analysis of panel 1 on NRG-L mice 
coincided with histopathological findings. Uninfected controls displayed no viral antigen, 
minimal-to-absent macrophages, and low expression of CD61, which predominated in 
endothelium and circulating platelets of interstitial capillaries. 2DPI xenografts displayed 
high amounts of viral Spike antigen, low macrophage numbers, and a noteworthy 
increase in CD61 immunoreactivity, particularly in intermediate to large vessel fibrin 
thrombi (Figure 21). 7DPI xenografts had lower amounts of spike antigen than 2DPI, 
correlating with our primary IHC findings. Some animals showed regional accumulation 
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of macrophages within airspaces as well as higher amounts of CD61 platelet 
accumulation than uninfected controls (Figure 22). Representative images of NRG-L 
panel 1 are shown in Figure 23.  
 
Figure 21. (A) 2DPI animal with extensive platelet rich thrombi in intermediate to large 
vessels as well as macrophage presence and viral antigen within bronchiole epithelium 
and necrotic debris within the airway. Total magnification, 100x. (B) Inset of image A 
total magnification, 200x. DAPI = grey, CD68 = red, CD61 = cyan, SARS-CoV-2 Spike 




Figure 22. (A) 7DPI animal with large macrophage infiltrate along with viral antigen and 
platelet rich capillary fibrin thrombi. Total magnification, 100x (B) Inset of image A total 
magnification, 200x. DAPI = grey, CD68 = red, CD61 = cyan, SARS-CoV-2 Spike = 






Figure 23. Representative multiplex fluorescent immunohistochemistry images of panel 
1 in NRGL-L. (A) Uninfected control, absence of SARS-CoV-2 Spike antigen, minimal-
to-absent macrophages, and low expression of CD61, which predominates within 
endothelium and circulating platelets of interstitial capillaries. Total magnification, 100x. 
(B) Inset of image A, total magnification 200x. (C ) 2DPI, SARS-CoV-2 Spike antigen in 
bronchiole epithelium and alveolar type II (AT2) pneumocytes, increase in CD61 
immunoreactivity especially in intermediate to large vascular thrombi, and low numbers 
of macrophages; total magnification, 100x. (D) Inset of image C; total mangification, 
200x. (E ) 7DPI, SARS-CoV-2 Spike antigen and regional accumulation of macrophages 
within airspaces; total magnification, 100x. (F) Inset of image E; total mangnification, 
200x. DAPI=grey, CD68=red, CD61=cyan, SARS-CoV-2 Spike=yellow, 
CD31=magenta, Prosurfactant Protein C (proSP-C)=green.  
 
SARS-CoV-2 Infection in HIS-NRGF-L mice fLX  
Fetal lung xenografts from HIS-NRGF-L mice displayed decreased influx of neutrophils 
(2 dpi, P=0.0120; 7 dpi, P=0.0031), intra-airway necrosis (7 dpi, P=0.0245), and 
syncytial cells (7 dpi, P=.0267) when compared to NRG-L fLX at 7 dpi. Hemorrhage was 
decreased at both 2 and 7 dpi for HIS-NRGF-L fLX compared to NRG-L fLx (2dpi, 
P=0.0066 and P=0.0228; 7 dpi, P=0.0066 and P=0.0228 respectively). Cumulative 
histology scores were decreased in HIS-NRGF-L fLX at 7 dpi, when compared to NRG-
L fLX (2 dpi, 0.0476; 7 dpi, P=0.0065) (Figure 24). Unique histomorphologic features 
observed but not captured by the semiquantitative scoring system in HIS-NRGF-L flX 
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included increased numbers of interstitial fibroblast, expansion of interstitium by mature 
collagen, and moderate to abundant mononuclear cell infiltrate morphologically 
consistent with lymphocytes and macrophages. The latter occasionally formed discrete 
lymphoid aggregates (Figure 25). Taken together these findings support the hypothesis 
that human myeloid and lymphoid infiltrates suppress or prevent the disparate host 

















































Figure 24. Two-way ANOVA with multiple comparisons of cumulative histopathologic 
score in HIS-NRGF-L vs. NRG-L mice at 2DPI (p=0.0476) and 7DPI (p=0.0228) 
showing that NRG-L mice exhibit more severe pathological lesions compared to dually 




Figure 25. Co-engraftment of NRG-L mice with human immune system (HIS-NRGF-L) 
prevents histologic phenotypes of diffuse alveolar damage (DAD) observed in NRG-L. (A 
& D). Increased mature collagen and fibroblast expand fLX interstitium, which contains 
mononuclear infiltrates consistent with lymphocytes and macrophages with absence of 
SARS-CoV-2 Spike antigen in a corresponding serial section. (B & E)  2 days post-
infection (DPI), interstitium and airspaces are expanded by abundant mononuclear cells 
morphologically consistent with macrophages and lymphocytes, with no evidence of 
diffuse alveolar damage (DAD), and mild SARS-CoV-2 Spike antigen in the cytoplasm of 
alveolar type II (AT2) pneumocytes. (C & F) 7 dpi, interstitium and airspaces are filled 
with moderate numbers of mononuclear cells morphologically consistent with 
macrophages and lymphocytes, with no evidence of DAD and mild SARS-CoV-2 Spike 
immunoreactivity of AT2 pneumocytes.  Hematoxylin and Eosin (H&E), total 
magnification, 200x, scale bar=100um. 
Humanization and Infection of HIS-NRGF-L fLX 
Uninfected, 2 and 7 dpi HIS-NRGF-L mice fLX displayed large numbers of human 
specific myeloid and lymphoid cell infiltrates (Figure 26). The most abundant cell 
population was CD68+ monocyte/macrophages, which routinely flooded airspaces, but 
were also observed in the interstitium. T cells were the second most abundant cell type, 
with higher numbers of CD3e+CD8- T cells (presumed CD4+ helper T-cells) compared 
to CD8+ cytotoxic T-cells. T cells were observed both in airspaces and within the 
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interstitium. CD20+ B-cells represented the smallest human leukocyte population 
infiltrating fLX. B cells formed dense tertiary lymphoid aggregates that contained lesser 
numbers of CD3e+CD8- T cells (presumed CD4+ helper T-cells). HIS-NRGF-L mice 
xenografts had decreased SARS-CoV-2 Spike immunoreactivity when compared to 
NRG-L mice xenograft (2DPI p=0.0392) (Figure 27). Spike antigen distribution was 
synonymous to that observed with NRG-L mice, confined to the cytoplasm of viable 
looking alveolar type II pneumocytes and bronchiole epithelium, but with little to no 
discernible cytopathic effect or neighboring intra-airspace necrosis. Taken together, these 
findings clearly illustrate the dual engraftment of NRG mice results in recruitment of 
abundant human myeloid and lymphoid populations that is affiliated with a decreased 
SARS-CoV-2 Spike antigen load and an absence of diffuse alveolar damage. 
Figure 26. Representative multiplex fluorescent immunohistochemistry images of panel 
2 in HIS-NRGF-L. (A) Uninfected control with no viral antigen, little-to-no B cells, and 
lower expression of T-cells (B) 2DPI  with presence of viral antigen, increased B cells, 
and formation of lymphoid aggregates. (C) 7DPI with presence of viral antigen, increased 
B cells, and formation of lymphoid aggregates.  DAPI – grey, CD3e – cyan, CD20 – 



























































Figure 27. Two-way ANOVA with multiple comparisons of Spike area quantification in 
HIS-NRGF-L and NRG-L mice at 2DPI and 7DPI. Viral antigen was increased in NRG-




Engraftment of NRG mice with human fetal lung tissue creates a small animal 
model permissive to SARS-CoV-2 infection  
In this study, we extensively characterized two small animal models as candidates for 
research surrounding SARS-CoV-2. As previously mentioned, there is a dire need for 
cost-effective small animal models of COVID19 that exhibit a consistent disease 
phenotype. We utilized histopathologic analysis and mIHC coupled with IA (image 
analysis) in order to assess their ability to recapitulate the histological hallmarks observed 
in human cases of COVID19. The use of human fetal lung xenografts was integral in 
circumnavigating some of the limitations presented by other small animal models. 
Utilization of fLX allows for direct insight into what infection looks like in human tissue 
rather than murine tissue altered to express human ACE2. Upon engraftment, NRG-L 
mice display no overt signs of graft vs. host disease and are able to integrate both murine 
and human blood vessels into the xenograft tissue. This blood vessel integration is also 
seen in HIS-NRGF-L mice; however, the dual engraftment of these mice renders them 
more susceptible to graft vs. host disease. In this study, none of the mice developed a 
xenograft aversion that was significant enough to affect the research. Though there is 
potential for graft vs. host disease, the likelihood of this occurring is rare, and the only 
noticeable consequence of dual engraftment is a slightly pro-fibrotic state compared to 
singly-engrafted NRG-L mice.  
Upon successful engraftment with fLX , mice are susceptible to infection with SARS-
CoV-2. The heterogenous landscape of the fetal lung xenograft is a contributing factor to 
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viral dissemination. We found that areas with predominant immature lung development 
express higher levels of ACE2 and Pro-SPC, rendering them more permissive to infection 
than mature tissues. Consistent with these findings, we determined that these immature 
areas (pseudoglandular) exhibit more severe disease and higher histopathological scores 
than more mature phenotypes (canalicular and saccular). Through a multi-modal 
approach, we were able to confirm viral presence using IHC, RT-qPCR, and TEM. Each 
modality provided insight into the mechanism of SARS-CoV-2 infection as seen within 
human tissues. IHC analysis using SARS-N and SARS-S antibodies revealed that viral 
antigen is most abundant in the acute phase of infection. At 2DPI, viral antigen is found 
mostly in the cytoplasm of type II pneumocytes, bronchiole epithelium, syncytial cells, 
and sporadically within necrotic debris. At 7DPI, viral antigen is found more 
predominantly in the airspaces along with necrotic cellular debris. We rationalize that the 
decrease in viral antigen observed at D7 is due to an innate immune response which 
inhibits further viral replication, but at the consequence of worsening histopathologic 
lesions. IHC findings correlated with RT-qPCR data that indicated significant levels of 
SARS-CoV-2 mRNA only in infected xenografts and not in uninfected controls. TEM 
analysis provided insight into the ultrastructural properties of SARS-CoV-2 infection 
within fLX. Virus particles observed within alveolar type II pneumocytes were in varying 
stages of maturation and confined to double-membrane bound vesicles, indicating 
productive infection within the fLX. Additional ultrastructural findings such as platelet 
aggregation and occasional thrombi were also indicative of a virally induced pro-
coagulative state. Altogether, these data provide extensive evidence for the capability of 
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NRG mice engrafted with human fetal lung tissue to become successfully infected with 
SARS-CoV-2 and develop morphologic phenotypes that are reported in humans having 
succumb to severe COVD-19.    
NRG-L mice infected with SARS-CoV-2 recapitulate hallmark lesions seen in severe 
COVID19 
The main histopathologic “umbrella” lesion seen in severe COVID19 is diffuse alveolar 
damage. Our semi-quantitative scoring aimed to categorize disease severity using a set of 
criteria specially designed to measure characteristics of DAD. By definition, diffuse 
alveolar damage represents a global injury to the gas-exchange surfaces due to disruption 
of the blood-air barrier leading to exudative edema and fibrosis, resulting in severely 
impaired blood and tissue oxygenation [45]. This manifests clinically as acute respiratory 
distress syndrome and is microscopically identifiable in affected lungs using H&E 
staining. Our semi-quantitative H&E analysis found that NRG-L mice infected with 
SARS-CoV-2 exhibit extensive histopathological manifestations consistent with DAD. 
Severity of lesions was variable, ranging from mild focal to severe generalized disease. 
The most statistically significant lesions observed in infected mice were neutrophil 
influx, intra-airspace necrosis, capillary fibrin thrombi, and presence of syncytial cells.  
Additionally, there were rare instances of coagulative necrosis and hyaline membrane 
formation in infected animals, which are also suggestive of significant pulmonary 
disease. Cumulative histology scores increased at both timepoints compared to controls, 
indicating progressive infection and increasing severity of disease. mIHC analysis 
corroborated what we saw histologically. Increased platelet aggregation revealed in 
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mIHC analysis is consistent with the pro-thrombotic state observed in human cases of 
COVID19. Additionally, increasing platelet aggregation observed with mIHC analysis of 
infected animals reflects increasing thrombi scores as captured with H&E semi-
quantitative analysis. A limitation for this model is the absence of human immune system 
components outside the fetal lung xenograft. The NRG-L model lacks humanization that 
goes beyond resident human cells within the fetal tissue. For this reason, this model isn’t 
useful in studying innate and adaptative immune response derived from peripheral 
myeloid and lymphoid populations in the context of SARS-CoV-2 infection. However, 
our findings indicate that NRG-L mice engrafted with human fetal lung tissues are a 
strong candidate for a reliable small-animal model of severe COVID19. These mice 
faithfully recapitulate the hallmark pathological lesions seen in cases of severe human 
disease. Additionally, this model allows for insight into infection within human tissue, 
which is not found in other animal models. Though these mice endure significant 
pulmonary disease within the xenografts, they consistently survive until late endpoints, 
which sets them aside from other models of severe disease. Taken together, the ability of 
these mice to consistently depict acute hallmark lesions of diffuse alveolar damage make 
them an excellent and dependable model for severe COVID19.  
HIS-NRGF-L mice do not exhibit the severe histopathologic phenotype observed in 
NRG-L mice 
When compared qualitatively and quantitatively, HIS-NRGF-L mice exhibited a much 
more moderate disease phenotype than NRG-L mice. Histopathologic characterization of 
HIS-NRGF-L mice resulted in much lower cumulative scores than NRG-L, indicating 
that these mice were not displaying severe disease. Though moderate, infection in these 
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animals resulted in lesser degrees of neutrophil influx, intra-airway necrosis, and 
syncytial cells when compared to uninfected controls. Interestingly, unique 
histomorphologic features such as interstitial fibroblasts, expansion of interstitium by 
mature collagen, and moderate to abundant mononuclear cell infiltrate were observed. It 
is feasible that these supplemental findings are a result of the dual-engrafted nature of this 
model acknowledging they were not observed in NRG-L mice.  
mIHC analysis played a large role in characterization of this model. The humanized 
immunopanel revealed that immune cell populations varied much less than expected 
among uninfected and infected animals that remained relatively stable temporally. Using 
the HALO™ cell phenotyping algorithm, we were able to generate quantitative outputs 
for each of the following cell types: CD3e+CD8- (presumed helper T-cells), CD8+ 
(cytotoxic T-cells), CD20+ (B-Cells), and CD68+ (macrophages). Macrophages were 
demonstrably the most abundant cell population found within these xenografts and were 
found primarily in the airspaces. T-cell populations varied, with higher counts of helper 
T-cells than cytotoxic T-cells. B-cells were the least abundant cell population analyzed in 
these samples. There was not any statistical significance determined between immune 
cell populations of uninfected controls and infected animals. Comparison to flow 
cytometry data taken from these animals was not highly correlated in the case of T-cells 
but was highly correlated for B-cells. This is likely since these xenografts are highly 
heterogenous and when they are sectioned for multiple analyses, data can vary depending 
on the landscape of the tissue examined. 
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Mitigation of severe disease in HIS-NRGF-L mice is due to mechanisms involving 
lymphoid and myeloid cell populations  
We can infer that the presence of myeloid and lymphoid populations within the HIS-
NRGF-L model exhibits a protective mechanism on the mice, resulting in a less-severe 
phenotype than observed in NRG-L mice. As previously mentioned, all data collected in 
this study indicates that HIS-NRGF-L mice do not exhibit the severe course of disease 
that is seen in all NRG-L mice. Because our methods of infection were identical between 
these two models, we can infer that the reason for this disparity between disease severity 
is a result of single and dual engraftment. The NRG-L mice lack any human or murine 
adaptive immune components. The only human immune cells present within these mice 
are the resident cells within the fetal xenograft itself. Because these mice rely solely on 
endogenous immune cells within the fLX, they lack the mechanisms necessary to 
mitigate infection, resulting in severe disease. Contrastingly, HIS-NRGF-L mice are 
dually-engrafted with components of the human immune system, meaning they have 
additional immune mechanisms to protect them from serious disease. This provides 
supplementary immune weapons that aid in mitigation of infection. Furthermore, we infer 
that macrophages and other myeloid lineage cells likely play a large role in this protective 
mechanism acknowledging that protection was afforded as early as 2PI. Macrophage 
populations were tremendously increased in HIS-NRGF-L mice compared to NRG-L 
mice. As this was by far the most abundant cell population in dually engrafted mice, it is 
reasonable to assume that they play a significant role in defense against infection. It is 
also possible that lymphoid cells contribute to disease mitigation as well. As our research 
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indicates, the highest human leukocyte population observed was CD3e+CD8- cells, or 
presumed helper T-cells. This coincides with prior research on related coronaviruses, all 
of which point to a primarily T-helper-cell mediated immune response in regards to 
adaptive immunity. It is possible that the presence of abundant myeloid cells and 
leukocyte cells near the site of viral replication plays a role in mitigating disparate innate 
immune response, and thus resulting in mild to moderate disease. The phenomenon of 
myeloid-driven viral mitigation that we observed in our mice can be tied back to human 
cases of severe COVID19 in elderly individuals. It has been reported that 
immunosenescence, or the gradual depletion of immune system that accompanies aging, 
can exacerbate infection with SARS-CoV-2. Typical hallmarks of age-related immune 
system impairment are decreased native T-cells in the periphery, decreased B-cell counts, 
decreased phagocytosis by macrophages, and low-grade chronic inflammation [46]. In 
the context of this research, the age-related impairment of myeloid cells is of particular 
interest. Decreased capacity to phagocytose cells by macrophages promotes a pro-
inflammatory state, such as the one observed in severe cases of COVID19. Age-related 
remodeling of neutrophils and macrophages could play a role in delayed resolution of 
inflammation in immunosenescent individuals. Studies have shown that macrophages 
from elderly lungs have more pronounced production of IL-6 and other pro-inflammatory 
cytokines when compared to younger lungs. IL-6 production inhibits production of 
interferon-γ, which is necessary for the activation of CD8+ T-cells. This could explain 
the lower numbers of cytotoxic T-cells observed in the COVID19 immune response as 
well as in our mouse models. Additionally, patients with severe COVID19 have a higher 
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IL-6/interferon-γ ratio than those with moderate disease [47]. These data indicate that the 
dysregulated function of macrophages in elderly individuals could play a role in their 
increased susceptibility to severe SARS-CoV-2 infection. This correlates with our 
findings that suggest macrophages to be a critical factor in the mitigation of severe 
disease. Furthermore, studies have shown that macrophages infected with SARS-CoV-2 
in-vitro have little-to-no induction of IFN-β, a crucial component of anti-viral innate 
immunity, suggesting that SARS-CoV-2 pathogenesis could greatly be impacted by 
macrophage-related activity [48]. A variety of literature has showed that dysregulation of 
macrophages has been observed as a common feature in severe COVID19. 
Immunological studies on patients with COVID19 have shown that patients with mild 
disease exhibit enriched anti-inflammatory monocyte-derived macrophages, while 
patients with severe disease exhibit resident pro-inflammatory macrophage populations. 
Additionally, macrophages can be infected with SARS-CoV-2, thus displaying a viral 
tool to manipulate host immunity and avoid an anti-viral response. A study performed on 
COVID19 in monocyte lineage cells revealed that SARS-CoV-2 does not replicate within 
these cells, but can infect monocytes and macrophages to stimulate cytokine release 
without any cytopathic effect [49]. Currently the immunoevasive tactic that SARS-Cov-2 
exerts on macrophages is not well-understood, but it is likely that viral manipulation of 
the macrophage response could play a role in disease severity [50]. It has been reported 
that SARS-CoV-2 drives monocytes and macrophages to induce partial immunoparalysis 
of the host, thus promoting the progression of infection [49]. Coupled with the data 
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obtained in this study, these findings indicate that a defective macrophage response could 
be a driving factor in predisposition to severe COVID19.  
Limitations and additional considerations 
Accompanying the many strengths of these mouse models are a few minor limitations. 
The potential for development of graft vs. host disease in HIS-NRGF-L mice is a 
consideration worth noting. Though the likelihood of this is rare and we did not observe 
this is any of the mice involved in this study, there is still a possibility of this occurring in 
this model due to dual-engraftment with human immune components. Additionally, the 
lack of clinical manifestations in these mice could be an issue for researchers looking to 
incorporate clinical disease symptoms as supplemental data. Because the infection in 
these mice is localized to the external grafts that are subcutaneously implanted on their 
bodies, the mice themselves do not become clinically ill. Therefore, although these 
models are excellent for pulmonary analysis, they are not viable for analyzing systemic 
effects of SARS-CoV-2 infection. Additionally, because infection is localized to 
xenografts, animals must be infected via subcutaneous injection into the xenograft. This 
is noteworthy because it is not the same route of infection observed in human cases of 
COVID19. However, this is the most effective way of ensuring successful infection with 
SARS-CoV-2 in fLX mice.  
The heterogeneity of fetal lung xenografts can also be an added potential limitation for 
these models. As previously mentioned, when xenografts are manually sectioned into 
smaller sections for multiple analyses, the resulting data can be influenced based on the 
landscape of the tissue section. This appeared to be the case for our mIHC panel 2 and 
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correlating flow cytometry data. We believe that in this case, the sections used for flow 
cytometry analysis were likely in different stages of maturation and infection than those 
studied in mIHC analysis, thus creating a discrepancy in data. This is an obvious issue, 
but is only relevant in studies that intend to perform multiple analyses on the same 
xenograft tissue.    
Statistically speaking, a limitation of this research was our inability to successfully 
quantify CD61 immunoreactivity in panel 1. Due to limitations within the HALO™ 
software, we weren’t able to produce an algorithm that accurately identified CD61+ 
staining. For this reason, we had to rely on qualitative analysis of CD61 staining and 
platelet accumulation as it pertained to thrombi in fLX. Though this limitation is minor, it 
prevented us from generating statistically relevant data regarding the pro-thrombotic state 
of these mice.  
From a scientific standpoint, usage of human tissues to study human disease is ideal. 
However, there are varying opinions surrounding the ethics of using human fetal tissue 
for scientific research. It is currently not illegal to do research involving human fetal 
tissue, however it is important to note that lack of government funding could be a 
potential limitation for research with these models. There are many different models for a 
plethora of diseases that implement the usage of human fetal tissues. In past decades, this 
type of research has proved to be undeniably valuable in diseases such as HIV and 
Hepatitis. Many within the scientific community agree that this work is extremely useful, 
so long as the research is carried out in an ethical and legal manner. However, recent 
action taken by government officials has thrust this issue into the limelight. Some policy 
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makers have taken steps to effectively ban government funded research on fetal tissue, 
citing that this work is “unnecessary” and “immoral.” [51]. This issue is largely 
contended within the Supreme Court as several lawmakers recognize the vast scientific 
benefits of this research, while others argue that it cannot be done in an ethical manner. 
Though entirely legal and regulated, it is necessary to acknowledge that government 
funding may not be available for this type of research.   
Future applications and additional research 
This research study was done as a multi-modal, interdisciplinary study that incorporated 
work from several different laboratories at Boston University and the NEIDL. The 
research highlighted in this thesis is a small piece of a large puzzle that encompasses a 
wide array of scientific applications. Aside from pathological evaluation, there are many 
other applications for these mice. The additional work done on these mice included 
transcriptomics, proteomics, gene ontology, flow cytometry, RT-qPCR, and several other 
scientific techniques. Using these practices, our colleagues were able to help classify 
gene signatures at different points of infection as well as identify a specific pathway as a 
central immunomodulatory mechanism that defines histopathological outcomes and 
control of SARS-CoV-2 infection. This highlights the potential of these mice to serve as 
an all-encompassing model of infection that can be utilized by several different scientific 
disciplines. As this was the first study to successfully characterize fLX implantation in 
NRG mice, the future applications are limitless. These mice can serve as a cost-effective 
small animal model for pulmonary infectious disease research. Additionally, our research 
underscores the benefits of a well-versed scientific collaboration between multiple 
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laboratories as a tool to accurately characterize an animal model from various scientific 
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